Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Is Tinospora cordifolia Responsible for Drug-induced Liver Injury?

Author(s): Preet Amol Singh* and Neha Bajwa

Volume 19, Issue 1, 2024

Published on: 03 March, 2023

Page: [8 - 10] Pages: 3

DOI: 10.2174/1574886318666230220120343

Price: $65

Abstract

A number of journal articles written by researchers claiming Tinospora cordifolia (Giloy) is to blame for liver damage have sparked a wide range of debates between Ayush and the allopathic medical community, particularly in India. Some even argue that promoting Giloy-based formulations to the general public is a bad idea. In this backdrop, the purpose of this essay is to provide a counter-narrative based on some of the major gaps in the research that implicated Giloy in Drug-induced Liver Injury (DILI). Time-tested herb, Giloy, which has been used for pharmacological benefits since antiquity, as well as clinical and toxicological evidence suggest that Giloy is safe, and the observed negative effects can be attributed to Tinospora crispa, a herb that resembles Tinospora cordifolia in appearance. Holding Giloy species to be detrimental is unjustifiable unless other variables such as authentication, standardization, Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), regularization of the market are considered. This article emphasizes the importance of strategic collaboration between plants and contemporary medicine in order to eliminate concerns about the use of Giloy by the general public.

« Previous Next »
Graphical Abstract

[1]
Singh PA, Bajwa N, Baldi A. Possible role of traditional systems of medicine to manage COVID-19: A review. Isr J Plant Sci 2021; 68(1-2): 3-28.
[http://dx.doi.org/10.1163/22238980-bja10021]
[2]
Nagral A, Adhyaru K, Rudra OS, Gharat A, Bhandare S. Herbal immune booster-induced liver injury in the COVID-19 pandemic - a case series. J Clin Exp Hepatol 2021; 11(6): 732-8.
[http://dx.doi.org/10.1016/j.jceh.2021.06.021] [PMID: 34230786]
[3]
Kulkarni AV, Hanchanale P, Prakash V, et al. Tinospora cordifolia (Giloy) induced liver injury during the COVID‐19 pandemic‐multicenter nationwide study from India. Hepatol Commun 2022; 6(6): 1289-300.
[http://dx.doi.org/10.1002/hep4.1904] [PMID: 35037744]
[4]
Kaur B. As COVID surged, India had a silent outbreak of giloyinduced liver injury. The Wire Science 2022. Available from: https://science.thewire.in/health/india-silent-outbreak-giloy-induced-livery-injury-ayurveda-ayush/
[5]
Rao U. Population meets database: Aligning personal, documentary and digital identity in aadhaar-enabled India. South Asia 2019; 42(3): 537-53.
[http://dx.doi.org/10.1080/00856401.2019.1594065]
[6]
Singh PA, Bajwa N, Chinnam S, Chandan A, Baldi A. An overview of some important deliberations to promote medicinal plants cultivation. J Appl Res Med Aromat Plants 2022; 31: 100400.
[http://dx.doi.org/10.1016/j.jarmap.2022.100400]
[7]
World Health Organization. WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. Geneva, Switzerland: World Health Organization 2003.
[8]
MoA. Guidelines for ayurveda practitioners for COVID-19. New- Delhi: Ministry of AYUSH 2020. Available from: https://aiia.go v.in/wp-content/uploads/2020/06/ayurveda.pdf
[9]
Larsen FS, Wendon J. Understanding paracetamol-induced liver failure. Intens Care Med 2014; 40(6): 888-90.
[http://dx.doi.org/10.1007/s00134-014-3293-9] [PMID: 24737263]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy